S-EPMC8576642 - Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE<sup>-/-</sup> mice by down-regulating PCSK9 via ERK1/2 pathway. - OmicsDI

Unknown

Dataset Information

Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE^-/- mice by down-regulating PCSK9 via ERK1/2 pathway.

ABSTRACT:

Background

It has been demonstrated that berberine (BBR), a kind of alkaloid derived from Chinese herbal medicine, has multiple pharmacological effects on human's diseases including anti-atherosclerosis action. However, although the previous studies showed that the beneficial impact of BBR on atherosclerosis might be associated with proprotein convertase subtilisin/kexin type 9 (PCSK9), the exact underlying mechanism are not fully determined. The present study aimed to investigate potential mechanisms of anti-atherosclerosis by BBR using ApoE^-/- mice.

Methods

The eight-week mice were divided into five groups: group 1 (wild type C57BL/6J mice with normal diet), group 2 (ApoE^-/- mice with normal diet), group 3 [ApoE^-/- mice with high-fat diet (HFD)], group 4 (ApoE^-/- mice with HFD, and treatment with low dose BBR of 50 mg/kg/d), and group 5 (ApoE^-/- mice with HFD, and treatment with high dose BBR of 100 mg/kg/d). After a 16-week treatment, the blood sample, aorta and liver were collected for lipid analysis, hematoxylin-eosin (HE) or oil red O staining, and Western blotting respectively. Besides, HepG2 Cells were cultured and treated with different concentrations of BBR (0, 5, 25 and 50 µg/mL) for 24 hours. Subsequently, cells were collected for real-time PCR or western blotting assays. Finally, the expression levels of PCSK9, LDL receptor (LDLR), ATP-binding cassette transporter A1 (ABCA1), ATP-binding cassette transporter G1 (ABCG1), and scavenger receptor class B type I (SR-BI) were examined.

Results

Fifty mg/kg/d and 100 mg/kg/d of BBR decreased total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) cholesterol (LDL-C), and increased high-density lipoprotein cholesterol (HDL-C) level. Moreover, BBR reduced aorta atherosclerotic plaque, and ameliorated lipid deposition in ApoE^-/- mice fed with HFD. Finally, in vitro study showed that BBR promoted intracellular cholesterol efflux, up-regulated LDLR and down-regulated PCSK9 expression via the ERK1/2 pathway in cultured HepG2 cells.

Conclusions

Data indicated that BBR significantly attenuated lipid disorder, reduced aortic plaque formation, and alleviated hepatic lipid accumulation in ApoE^-/- mice fed with HFD, which was associated with down-regulation of PCSK9 through ERK1/2 pathway.

SUBMITTER: Ma CY

PROVIDER: S-EPMC8576642 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE<sup>-/-</sup> mice by down-regulating PCSK9 via ERK1/2 pathway.

Ma Chun-Yan CY Shi Xiao-Yun XY Wu Ya-Ru YR Zhang Yue Y Yao Yu-Hong YH Qu Hui-Lin HL Zhang Wei W Guo Yuan-Lin YL Xu Rui-Xia RX Li Jian-Jun JJ

Annals of translational medicine 20211001 20

<h4>Background</h4>It has been demonstrated that berberine (BBR), a kind of alkaloid derived from Chinese herbal medicine, has multiple pharmacological effects on human's diseases including anti-atherosclerosis action. However, although the previous studies showed that the beneficial impact of BBR on atherosclerosis might be associated with proprotein convertase subtilisin/kexin type 9 (PCSK9), the exact underlying mechanism are not fully determined. The present study aimed to investigate potent ...[more]

Similar Datasets

Project description:BackgroundAtherosclerosis (AS) is a major contributor to vascular disorders and represents a significant risk to human health. Currently, first-line pharmacotherapies are associated with substantial side effects, and the development of atherosclerosis is closely linked to dietary factors. This study evaluated the effects of a dietary supplement, EsV3, on AS in apolipoprotein E (ApoE) -/- model mice.MethodsThe study utilized a high-fat diet-induced ApoE-/- hyperlipidemic mouse model. EsV3 was administered in prophylactic (P-EsV3) and therapeutic regimens for 16 and 12 weeks, respectively, with distinct high- and low-dose groups (0.36 and 1.8 g/kg/day). Serum lipid levels were measured and monitored for body weight and food consumption alterations in murine models. Aortic oil red O staining was conducted to assess plaque formation and calculate the plaque-to-vessel area ratio. Liver tissue changes were examined via HE staining. Moreover, serum oxidative stress markers (MDA, GSH, SOD) were measured to evaluate oxidative damage and lipid metabolism.ResultsBoth atorvastatin and P-EsV3 treatments significantly lowered TC, TG, and LDL-C levels, with P-EsV3-H enhancing HDL-C levels (P < 0.05). Prophylactic EsV3 administration was more effective than therapeutic administration in regulating TG and LDL-C levels and had comparable effects to atorvastatin on TC and HDL-C. All treatment groups exhibited reduced body weight compared to the model group, with no significant differences in food intake. Additionally, EsV3 administration significantly reduced the aortic plaque area and liver lipid droplets compared to the model group, while mitigating oxidative stress, as evidenced by decreased MDA levels and increased SOD and GSH levels, with outcomes comparable to those observed with atorvastatin.ConclusionsIn ApoE-/- hyperlipidemic mice, EsV3 improved lipid profiles and reduced aortic plaque formation. EsV3's effects, attributed partly to its antioxidant properties, were comparable to atorvastatin, suggesting its potential as a preventive and therapeutic agent for hyperlipidemia and atherosclerosis.